Variant · Snv

KRAS G12V

CI-VAR-00001620Explore in graph →NP_004976.2:p.Gly12ValNM_004985.4:c.35G>TClinVar 12583 CIViC 425 rs121913529

Curated evidence

Evidence by cancer (36 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–36 of 36 evidence items across 6 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma6
KRAS G12V	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID987 Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC. Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12… (full text at CIViC) PMID 26372703 · Renaud et al., 2015 · Open in CIViC	civic
KRAS G12V	Crizotinib	Predictive	C	Supports Resistance	3	submitted	EID8891 This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient harbored KRAS G12V co-mutation … (full text at CIViC) PMID 22235099 · Doebele et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12583	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Carcinoma of pancreas; Nevus sebaceous; Juvenile myelomonocytic leukemia; Non-small cell lung carcinoma; Cerebral arteriovenous malformation; Chronic myeloid leukemia; Lung sarcomatoid carcinoma; Linear nevus sebaceous syndrome; RASopathy; Neoplasm; Colorectal cancer; Ovarian mucinous adenocarcinoma; Adenocarcinoma of the large intestine; Germinoma	germline/somatic

Malignant Colon Neoplasm2
KRAS G12V	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3931 In a phase 3 clinical study,�BRAF wild-type stage III colon cancer patients harboring KRAS G12V mutation (n=213) and treated with cetuximab plus standard chemotherapy were associated with decreased di… (full text at CIViC) PMID 24687927 · Yoon et al., 2014 · Open in CIViC	civic
KRAS G12V	Regorafenib Anhydrous	Predictive	D	Supports Sensitivity Response	—	submitted	EID3932 In an in vitro study, a SW480 cell line expressing KRAS G12V mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-type KRAS. Resist… (full text at CIViC) PMID 26865419 · Takigawa et al., 2016 · Open in CIViC	civic

Malignant Colon Neoplasm2

KRAS G12V

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3931

In a phase 3 clinical study,�BRAF wild-type stage III colon cancer patients harboring KRAS G12V mutation (n=213) and treated with cetuximab plus standard chemotherapy were associated with decreased di… (full text at CIViC)

PMID 24687927 · Yoon et al., 2014 · Open in CIViC